Garry E. Menzel
2012 - Regulus Therapeutics
In 2012, Garry E. Menzel earned a total compensation of $903.7K as Chief Operating Officer and Executive Vice President, Finance at Regulus Therapeutics, a 104% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $140,566 |
|---|---|
| Option Awards | $430,002 |
| Salary | $327,659 |
| Other | $5,488 |
| Total | $903,715 |
Menzel received $430K in option awards, accounting for 48% of the total pay in 2012.
Menzel also received $140.6K in non-equity incentive plan, $327.7K in salary and $5.5K in other compensation.
Rankings
In 2012, Garry E. Menzel's compensation ranked 6,537th out of 11,487 executives tracked by ExecPay. In other words, Menzel earned more than 43.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,537 out of 11,487 | 43rd |
Division Manufacturing | 2,341 out of 4,253 | 45th |
Major group Chemicals And Allied Products | 591 out of 1,203 | 51st |
Industry group Drugs | 404 out of 925 | 56th |
Industry Pharmaceutical Preparations | 317 out of 700 | 55th |
Source: SEC filing on April 30, 2013.
Menzel's colleagues
We found two more compensation records of executives who worked with Garry E. Menzel at Regulus Therapeutics in 2012.